DFIB Cardiac Science (MM)

Cardiac Science to Present at Wells Fargo Securities' 2005 Healthcare Conference IRVINE, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Cardiac Science Inc. (NASDAQ:DFIB) today announced that Chairman and CEO Raymond W. Cohen is scheduled to make an investor presentation at Wells Fargo Securities' 2005 Healthcare Conference on Wednesday, March 2, 2005 at 11:15 a.m. Eastern Time. The conference is being held at the St. Regis Hotel in New York City. A live webcast of the Company's presentation at the conference will be available via a link provided at the Company's website at http://www.cardiacscience.com/. An archive of the presentation will begin shortly after the presentation time and will be available for 30 days. About Cardiac Science Cardiac Science develops, manufactures and markets a complete line of Powerheart(R) brand, automated public access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The company makes the Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit http://www.cardiacscience.com/ or call 1.949.797.3800. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to the achievement of future revenue growth based on the expanded agreement with GE. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward- looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2003, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission. Contact: Matt Clawson (Investors) Michael D. Gioffredi Allen & Caron Inc Chief Marketing Officer (949) 474-4300 Cardiac Science, Inc. (949) 797-3800 DATASOURCE: Cardiac Science Inc. CONTACT: Investors, Matt Clawson of Allen & Caron Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or Michael D. Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright